Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Controlled, Multiple Centers Clinical Study of the Efficacy and Safety for Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis (TAK): The VIVA-TAK Ttrial

NCT07451665 is registered in ClinicalTrials.gov with Chinese SLE Treatment And Research Group as lead sponsor.

NCT NCT07451665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07451665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Controlled, Multiple Centers Clinical Study of the Efficacy and Safety for Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis (TAK): The VIVA-TAK Ttrial
Lead sponsor
Chinese SLE Treatment And Research Group
Phase
Phase 4
Overall status
Not yet recruiting
Start date
April 1, 2026
Completion date
March 31, 2029
Enrollment
180 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

takayasu arteritis (tak)